Sionna Therapeutics, Inc. (SION) Stock Price & How to Invest

Sionna Therapeutics (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF). Its lead candidates, SION-719 and SION-451, are first-in-class stabilizers of the nucleotide-binding domain 1 (NBD1) of the CFTR protein, the region disrupted by the F508del mutation that affects roughly 90% of CF patients. The thesis is that stabilizing NBD1 could restore CFTR function toward wild-type levels and, added on top of the current standard of care (Vertex's Trikafta), deliver clinically meaningful improvement. The company went public in February 2025 at $18.00 per share, raising about $219 million in an upsized IPO.

The investment picture is that of a typical high-variance, pre-revenue biotech. Sionna has no product sales; it reported a 2025 net loss of about $75 million and a Q1 2026 net loss of roughly $27 million, funded by roughly $290 million of cash and marketable securities that management expects to support operations into 2028. The stock carries a market capitalization near $1.8 billion on that unproven pipeline, so the valuation reflects expectations rather than results. Topline Phase 2a data for SION-719 (the PreciSION CF trial, enrollment complete) and Phase 1 combination data for SION-451 are expected in summer 2026, making the stock a concentrated bet on those readouts.

As a pre-revenue clinical-stage biotech, Sionna faces the standard binary risk that a trial disappoints, which could sharply reduce the stock's value given its roughly $1.8 billion market cap sits on an unproven pipeline. The NBD1 mechanism has not yet been validated in a large controlled CF trial, and add-on benefit over the already highly effective standard of care may be hard to demonstrate. Vertex is a deeply entrenched incumbent with next-generation modulators of its own. Cash runs into 2028, so additional financing and dilution are likely before any product could reach market. Regulatory, manufacturing, and enrollment setbacks could each delay timelines or raise costs.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sionna Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (no approved product)
• Net loss (FY2025): ~$75M
• Net loss (Q1 2026): ~$27M
• Cash & marketable securities: ~$290M (into 2028)
• Market cap: ~$1.8B
• IPO (Feb 2025): ~$219M at $18.00/share

SION has no product revenue and runs steady operating losses, which is normal for a clinical-stage biotech funding trials. Traditional earnings multiples do not apply; the market is pricing the probability-weighted value of the CF pipeline. The roughly $1.8 billion market cap against about $290 million of cash implies large expectations riding on the summer 2026 data.

There are three common ways to get SION exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SION sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SION fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

SION is a pre-revenue cystic fibrosis biotech whose value hinges almost entirely on whether its NBD1 stabilizers read out well against Vertex's standard of care.

Whether SION is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SION a buy?, and where the stock could go from here in the SION stock forecast.

For income investors, whether SION pays a dividend and how the payout looks is covered in does SION pay a dividend?